# An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)

> **NCT07344376** · PHASE3 · COMPLETED · sponsor: **GC Biopharma Corp** · enrollment: 30 (actual)

## Conditions studied

- MPS II
- Hunter Syndrome (MPS II)
- Hunter Syndrome
- Hunterase
- GC1111

## Interventions

- **DRUG:** Hunterase

## Key facts

- **NCT ID:** NCT07344376
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-23
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07344376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07344376, "An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07344376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*